



Receipt

PATENT
Our Docket: P-IX 2405

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
William D. Huse)
Serial No.: 08/790,540)
Filed: January 30, 1997)
For: ANTI- α V β 3 RECOMBINANT)
HUMAN ANTIBODIES,)
NUCLEIC ACIDS ENCODING)
SAME AND METHODS OF USE)

Group Art Unit: 1644

Examiner: P. Gambel

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on October 5, 2001.

By: Deborah L. Cadena
Deborah L. Cadena, Reg. No. 44,048

Commissioner for Patents
Washington, D.C. 20231

October 5, 2001
Date of Signature

ATTN: Office of Initial Patent
Examination Customer Service Center

CORRECTION OF FILING RECEIPT

Sir:

The filing receipt issued in the above-identified application is incorrect for the reasons set forth below:

The filing receipt issued in the above-identified application shows total claims as 25, and the independent claims as 9. This is incorrect. As shown on the attached copy of the Continued Prosecution Application Request Transmittal for the above-identified application (Exhibit A), which was filed with the application on December 7, 2000, the total claims should be 31, and the independent claims should be 12.

The filing receipt issued in the above-identified application does not reflect the proper filing fee received. As shown on the attached Exhibit A, and the attached copy of the



Inventors: William D. Huse
Serial No.: 08/790,540
Filing Date: January 30, 1997
Page 2

postcard stamped by the U.S. Patent and Trademark Office (Exhibit B), a check in the amount of \$3,018.00 to cover the filing fee of \$1,628.00, and the four-month extension of time fee of \$1,390.00 was received by the USPTO on December 8, 2000.

The filing receipt does not reflect that this application no longer claims small entity status. See attached copy of the Continued Prosecution Application Request Transmittal for Filing (Exhibit A), paragraph 3, which was filed with the application on December 7, 2000.

Attached is a copy of the Filing Receipt with the changes noted thereon. Applicants accordingly request that these corrections be made of record and that an amended Filing Receipt be issued.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge any fees to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: October 5, 2001

Deborah L. Cadena
Registration No. 44,048
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

Campbell & Flores LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
USPTO CUSTOMER NO. 23601



COPY

CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL

(only for Continuation or Divisional
applications under 37 CFR 1.53(d))

Submit an original and a duplicate for
fee processing

Docket No.: P-IX 2405

Prior Application Info:

Examiner: P. Gambel

Group/Art Unit: 1644

Check box, if applicable:

☐ DUPLICATE

Address to: COMMISSIONER FOR PATENTS

Box CPA

Washington, D.C. 20231



23601

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER: EL 690 156 380 US

DATE OF DEPOSIT: December 7, 2000

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS-MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER
37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE, AND IS
ADDRESSED TO: BOX CPA, COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231.

Elizabeth S. Conaughton

(TYPED OR PRINTED NAME OR PERSON MAILING PAPER OR FEE)

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

This is a request for filing a
 X continuation divisional

application under 37 C.F.R. 1.53(d), of pending prior application
serial no. **08/790,540**, filed on **January 30, 1997** (list only
immediate prior application).

Title: **ANTI- α V β 3 RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS
ENCODING SAME AND METHODS OF USE**

Inventor(s) (full name of each inventor): **WILLIAM D. HUSE**

The above-identified prior application, in which no
payment of the issue fee, abandonment of, or termination of
proceedings has occurred, is hereby expressly abandoned as of the
filing date of this request for a CPA. The above-identified
prior application is a non-provisional application that is
either: (1) complete as defined by 37 CFR 1.51(b) or (2) the
national stage of an international application in compliance with
35 U.S.C. 371.

1. X Enter the unentered amendment previously filed on
June 7, 2000, under 37 C.F.R. 1.116 in the prior non-
provisional application.
2. A preliminary amendment is enclosed.
3. Small entity status:
 - a. A small entity statement is enclosed.
 - b. A small entity statement was filed in the prior non-
provisional application, serial no. , and
such status is still proper and desired.
 - c. X is no longer claimed.
4. The prior application is assigned of record to Ixsys,
Incorporated.

EXHIBIT A

Inventors: William D. Huse
Serial No.: 08/790,540
Filing Date: January 30, 1997
Page 2

5. The power of attorney in the prior application is to Cathryn Campbell, Reg. No. 31,815, David A. Gay, Reg. No. 39,200.
6. ☐ A new power of attorney or authorization of agent is enclosed.
7. This application is filed by fewer than all the inventors named in the prior application (37 CFR 1.53(d)(4)).
a. ☐ DELETE the following inventor(s) in the prior non-provisional application: _____
b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
8. ☒ A return receipt postcard is enclosed.
9. ☐ A Patent Application Bibliographic Data Sheet is enclosed.
10. ☐ Receipt for Facsimile Transmitted CPA (PTO/SB/29A) is enclosed.
11. ☐ Request for Nonpublication and Certification is enclosed.

The filing fee is calculated below:

	NUMBER FILED		NUMBER EXTRA		RATE	FEE
TOTAL CLAIMS	31-20	=	11	x	\$9 \$18	\$198
INDEPENDENT CLAIMS	12-3	=	9	x	\$40 \$80	\$720
MULTIPLE DEPENDENT CLAIMS _____ YES _____ NO					\$135 \$270	\$0
BASIC FEE					\$355 \$710	\$710
TOTAL FEE						\$1628

12. ☒ An Information Disclosure Statement and a copy of one reference are enclosed.
13. ☒ A Form PTO 1449 is enclosed.
14. ☒ 5 sheets of Formal Drawings are enclosed.
15. ☒ A check is enclosed in the amount of \$3018.00, of which \$1628.00 covers the additional claims and filing fees, and \$1390.00 covers the large entity, four-month extension of time.
16. ☐ The filing fee is not enclosed. Do not charge our deposit account.

EXHIBIT A

Inventors: William D. Huse
Serial No.: 08/790,540
Filing Date: January 30, 1997
Page 3


17. ☒ The Commissioner is hereby authorized to charge fees under 37 C.F.R. 1.16 and 1.17 which may be required or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
18. ☒ The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Address all future communications to:

Cathryn Campbell
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive, 7th Floor
San Diego, California 92122
telephone: (858) 535-9001
facsimile: (858) 535-8949
USPTO CUSTOMER NO. 23601

Respectfully submitted,

Date: December 7, 2000


Deborah L. Cadena
Registration No. 44,048
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122

___ inventor(s) ☒ attorney or agent of record
___ assignee of complete ___ filed under Sec. 1.34(a)
 interest

EXHIBIT A



Please acknowledge receipt of the accompanying:

- ☒ Continuation ☐ Divisional
☒ Transmittal Form 37 C.F.R. 1.53(d) (CPA) (in duplicate)

Prior App. Ser. No. 08/790,540
Prior App. filing date January 30, 1997

Inventors William D. Huse
Title ANTI- α V β 3 RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS
ENCODING SAME AND METHODS OF USE


No. of Pending Claims 31

- ☐ Preliminary Amendment ☐ Small Entity Statement
☒ Petition for a four-month Extension of Time (in duplicate)
☒ This return receipt postcard
☒ Other Information Disclosure Statement, including a copy of one
reference and a Form 1449;
☒ 5 Sheets of Formal Drawings
☒ Fee \$ 3018.00 enclosed Check No.: 025459
☒ Certificate of Express Mailing No.: EL 690 156 380 US
Our Docket No. P-IX 2405 Date Mailed: December 7, 2000
Client: Applied Molecular Evolution (IXSYS, INC.)
Atty/Secy DLC/esc

Place your receiving date stamp including Serial No. hereon and return this card.

COPY

EXHIBIT B



COPY

Page 1 of 4

not
o/c
cc
P

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
08/790,540	01/30/1997	1644	2113 1628	P-IX-2405	5	25 31	9 12

CONFIRMATION NO. 1555

23601
CAMPBELL & FLORES LLP
4370 LA JOLLA VILLAGE DRIVE
7TH FLOOR
SAN DIEGO, CA 92122

CORRECTED FILING RECEIPT



OC000000005914512

Date Mailed: 03/29/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

WILLIAM D. HUSE, DEL MAR, CA;

Continuing Data as Claimed by Applicant

Foreign Applications

If Required, Foreign Filing License Granted 07/09/1997

Projected Publication Date: 07/05/2001

Non-Publication Request: No


Early Publication Request: No

~~SMALL ENTITY~~ NO

Title

ANTI-ALPHA V BETA 3 RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS
ENCODING SAME AND METHODS OF USE

Preliminary Class



424

Data entry by : NGUYEN, TRAC

Team : OIPE

Date: 03/29/2001





LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231